Technical Analysis for APLT - Applied Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
30.47 | -2.40% | -0.75 |
APLT closed down 2.4 percent on Friday, July 10, 2020, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical APLT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | -2.40% | |
| Wide Bands | Range Expansion | -2.40% | |
| Oversold Stochastic | Weakness | -2.40% | |
| New Downtrend | Bearish | -5.81% | |
| 200 DMA Support | Bullish | -5.81% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Biopharmaceutical Organ Systems Diabetes Diabetes Mellitus Cardiovascular Disease Diabetic Retinopathy Diabetic Peripheral Neuropathy Preclinical Stage Products Retinopathy Novel Products Peripheral Neuropathy
Biopharmaceutical Organ Systems Diabetes Diabetes Mellitus Cardiovascular Disease Diabetic Retinopathy Diabetic Peripheral Neuropathy Preclinical Stage Products Retinopathy Novel Products Peripheral Neuropathy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 57.39 |
| 52 Week Low | 8.36 |
| Average Volume | 226,617 |
| 200-Day Moving Average | 32.54 |
| 50-Day Moving Average | 42.08 |
| 20-Day Moving Average | 38.31 |
| 10-Day Moving Average | 33.34 |
| Average True Range | 3.27 |
| ADX | 27.24 |
| +DI | 13.53 |
| -DI | 31.88 |
| Chandelier Exit (Long, 3 ATRs ) | 40.08 |
| Chandelier Exit (Short, 3 ATRs ) | 38.27 |
| Upper Bollinger Band | 49.68 |
| Lower Bollinger Band | 26.94 |
| Percent B (%b) | 0.16 |
| BandWidth | 59.37 |
| MACD Line | -3.33 |
| MACD Signal Line | -2.49 |
| MACD Histogram | -0.8401 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 32.20 | ||||
| Resistance 3 (R3) | 32.28 | 31.78 | 31.91 | ||
| Resistance 2 (R2) | 31.78 | 31.34 | 31.74 | 31.81 | |
| Resistance 1 (R1) | 31.13 | 31.07 | 30.88 | 31.05 | 31.72 |
| Pivot Point | 30.63 | 30.63 | 30.51 | 30.59 | 30.63 |
| Support 1 (S1) | 29.98 | 30.19 | 29.73 | 29.90 | 29.22 |
| Support 2 (S2) | 29.48 | 29.92 | 29.44 | 29.13 | |
| Support 3 (S3) | 28.83 | 29.48 | 29.03 | ||
| Support 4 (S4) | 28.75 |
